Intended use:
For in vitro diagnostic use. RIDA®GENE Faecalibacterium prausnitzii is a multiplex real-time PCR for the direct qualitative and quantitative detection of Faecalibacterium prausnitzii DNA in human stool samples.
General information:
Faecalibacterium prausnitzii is a gram-positive, strictly anaerobic, commensal bacterium and belongs to the family of Clostridiacea. F. prausnitzii is one of the most important bacteria in the human gut flora and makes up to 5-10 % of the total number of bacteria detected in stool samples from healthy humans. F. prausnitzii localization seemed to depend upon anaerobic conditions only found in the lower gut. In early infancy the number of F. prausnitzii is very low and increases after the establishment of primocolonizing bacteria. They are strictly anaerobic and thus difficult to grow in culture. Consequently, this explains why the mechanisms of its protection potential are still poorly understood. F. prausnitzii produces butyric acid derivates e.g. butyrate, which are essential for the intestinal activity. Butyrate plays an important role for the metabolism in the colon. They serve as energy sources for the colonocytes and have anti-inflammatory effects and maintain the activity of bacterial enzymes and protects the digestive system against intestinal pathogens. Changes in the number of F. prausnitzii are an indication for dysbiosis in the human gut flora. A significant reduction of F. prausnitzii is detected by patients with diabetes and chronic inflammatory intestinal disorders (Morbus Crohn, Colitis ulcerosa, IBS). For the latter case, the intestinal barrier is disrupted or rather the intestinal wall gets more permeable. This leads to an unregulated mass exchange and causes diarrheal diseases and inflammatory reactions.
Art. No. | PG0155 |
---|---|
Test format | real-time PCR with 100 reactions |
Shelf life | 24 month after production |
Sensitivity | Analytical sensitivity: ≥ 10 DNA copies per reaction |
Instructions | |
---|---|
SDS |
Dear customers,
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal eifu.r-biopharm.com.